CATALOGO DEI PRODOTTI DELLA RICERCA

MELISI, Davide
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 6.703
NA - Nord America 5.977
AS - Asia 4.676
SA - Sud America 641
AF - Africa 93
OC - Oceania 13
Continente sconosciuto - Info sul continente non disponibili 5
Totale 18.108
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.881
RU - Federazione Russa 2.754
SG - Singapore 1.891
CN - Cina 1.679
GB - Regno Unito 1.203
IT - Italia 551
BR - Brasile 520
SE - Svezia 512
DE - Germania 432
HK - Hong Kong 428
IE - Irlanda 363
FR - Francia 350
VN - Vietnam 278
FI - Finlandia 249
KR - Corea 125
UA - Ucraina 76
CA - Canada 56
NL - Olanda 43
AR - Argentina 42
JP - Giappone 39
IN - India 37
AT - Austria 30
ID - Indonesia 29
PL - Polonia 29
ZA - Sudafrica 29
BD - Bangladesh 28
TR - Turchia 28
MX - Messico 25
EC - Ecuador 21
BE - Belgio 20
ES - Italia 18
IQ - Iraq 18
TG - Togo 17
BJ - Benin 15
VE - Venezuela 15
PY - Paraguay 13
SA - Arabia Saudita 13
AU - Australia 12
CH - Svizzera 12
CL - Cile 12
CZ - Repubblica Ceca 11
JO - Giordania 10
MA - Marocco 10
PK - Pakistan 10
LT - Lituania 9
PT - Portogallo 9
IR - Iran 8
PE - Perù 7
AE - Emirati Arabi Uniti 6
CO - Colombia 6
UZ - Uzbekistan 6
AZ - Azerbaigian 5
DZ - Algeria 5
KG - Kirghizistan 5
BG - Bulgaria 4
EG - Egitto 4
EU - Europa 4
KE - Kenya 4
LK - Sri Lanka 4
SN - Senegal 4
UY - Uruguay 4
AL - Albania 3
AM - Armenia 3
BY - Bielorussia 3
DK - Danimarca 3
EE - Estonia 3
HN - Honduras 3
KZ - Kazakistan 3
LB - Libano 3
NP - Nepal 3
QA - Qatar 3
RO - Romania 3
CR - Costa Rica 2
DO - Repubblica Dominicana 2
GE - Georgia 2
HU - Ungheria 2
IL - Israele 2
LV - Lettonia 2
NO - Norvegia 2
OM - Oman 2
PA - Panama 2
PH - Filippine 2
PS - Palestinian Territory 2
A2 - ???statistics.table.value.countryCode.A2??? 1
BA - Bosnia-Erzegovina 1
BO - Bolivia 1
BS - Bahamas 1
CI - Costa d'Avorio 1
DM - Dominica 1
ET - Etiopia 1
GD - Grenada 1
GI - Gibilterra 1
HT - Haiti 1
IM - Isola di Man 1
JM - Giamaica 1
KH - Cambogia 1
KW - Kuwait 1
LU - Lussemburgo 1
MK - Macedonia 1
MY - Malesia 1
Totale 18.100
Salva come PNG Salva come JPEG
Città #
Southend 1.033
Moscow 933
Singapore 910
Chandler 841
Dallas 627
Ashburn 625
Jacksonville 488
Hong Kong 427
Woodbridge 400
Dublin 361
Ann Arbor 268
Beijing 268
Jinan 162
The Dalles 154
Verona 139
Houston 136
Lawrence 132
Princeton 132
Wilmington 126
Munich 121
Los Angeles 107
Ho Chi Minh City 101
Shenyang 97
New York 95
Nanjing 89
Tianjin 76
Helsinki 73
Hebei 66
Buffalo 64
Redondo Beach 54
Changsha 53
Columbus 52
São Paulo 52
Hanoi 51
Zhengzhou 46
Sindelfingen 45
Haikou 44
Turku 42
Milan 40
Taiyuan 39
Hangzhou 38
Guangzhou 36
Redwood City 35
Nanchang 31
Ningbo 31
Santa Clara 31
Taizhou 31
Frankfurt am Main 30
London 30
Tokyo 30
Seattle 26
Fuzhou 25
Rome 24
Warsaw 24
Washington 24
Nuremberg 23
Boardman 22
Redmond 22
San Francisco 22
Denver 21
Kent 21
Atlanta 20
Brussels 20
Dong Ket 20
Jiaxing 20
Johannesburg 20
Montreal 20
Rio de Janeiro 20
Toronto 20
Council Bluffs 19
Jakarta 19
Chicago 18
Brooklyn 17
Lomé 17
Norwalk 17
Amsterdam 15
Boston 15
Brasília 15
Cotonou 15
Belo Horizonte 14
Bologna 14
Dongguan 14
Phoenix 14
Seoul 14
Vienna 14
Lanzhou 13
Orem 13
San Jose 13
Baghdad 12
Stockholm 12
Campinas 11
Falkenstein 11
Zurich 11
Amman 10
Ankara 10
Chennai 10
Da Nang 10
Mexico City 10
Quito 10
Monza 9
Totale 10.722
Salva come PNG Salva come JPEG
Nome #
An FGFR3 autocrine loop sustains acquired resistance to trastuzumab in gastric cancer patients 288
A circulating TH2 cytokines profile predicts survival in patients with resectable pancreatic adenocarcinoma 260
Combined inhibition of IL1, CXCR1/2, and TGFβ signaling pathways modulates in-vivo resistance to anti-VEGF treatment 238
Anti-VEGF treatment-resistant pancreatic cancers secrete proinflammatory factors that contribute to malignant progression by inducing an EMT cell phenotype. 227
A phase II study of liposomal irinotecan with 5-fluorouracil, leucovorin and oxaliplatin in patients with resectable pancreatic cancer: the nITRO trial 217
Adipocytes sustain pancreatic cancer progression through a non-canonical WNT paracrine network inducing ROR2 nuclear shuttling 204
Outcomes of Primary Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma 202
Multigene mutational profiling of cholangiocarcinomas identifies actionable molecular subgroups 195
A Case-Matched Gender Comparison Transcriptomic Screen Identifies eIF4E and eIF5 as Potential Prognostic Markers in Male Breast Cancer 183
NF-κB as a target for pancreatic cancer therapy. 180
Angiopoietin-Like Proteins in Angiogenesis, Inflammation and Cancer 177
A selective cyclooxygenase-2 inhibitor combined with the epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) ZD1839 ('Iressa') and protein kinase A antisense causes cooperative tumor growth inhibition after oral administration 173
A phase II trial of the FGFR inhibitor pemigatinib in patients with metastatic esophageal-gastric junction/gastric cancer trastuzumab resistant: the FiGhTeR trial 170
An angiopoietin-like protein 2 autocrine signaling promotes EMT during pancreatic ductal carcinogenesis 168
A novel modified CpG agonist of TLR-9 inhibits EGF receptor signalling and synergistically enhances antitumor activity of cetuximab and irinotecan eradicating colon cancer xenografts 167
Prognostic impact of early nutritional support in patients affected by locally advanced and metastatic pancreatic ductal adenocarcinoma undergoing chemotherapy 167
Homeobox B9 Mediates Resistance to Anti-VEGF Therapy in Colorectal Cancer Patients 166
Induction of immunosuppressive functions and NF-κB by FLIP in monocytes 166
Emerging pathways and future targets for the molecular therapy of pancreatic cancer. 165
Organisational challenges, volumes of oncological activity and patients' perception during the severe acute respiratory syndrome coronavirus 2 epidemic 165
Anti- VEGF treatment resistant pancreatic cancers secrete proinflammatory factors that contribute to malignant progression by inducing an EMT cell phenotype 164
Pancreatic Cancer and Obesity: Molecular Mechanisms of Cell Transformation and Chemoresistance 164
Correlation of MR features and histogram-derived parameters with aggressiveness and outcomes after resection in pancreatic ductal adenocarcinoma 161
Organoid-Transplant Model Systems to Study the Effects of Obesity on the Pancreatic Carcinogenesis in vivo 160
Current Strategies to Overcome Resistance to ALK-Inhibitor Agents 159
Antitumor activity of ZD6126, a novel vascular-targeting agent, is enhanced when combined with ZD1839, an epidermal growth factor receptor tyrosine kinase inhibitor, and potentiates the effects of radiation in a human non-small cell lung cancer xenograft model. 159
Pancreatic ductal adenocarcinoma cell lines display a plastic ability to bi‑directionally convert into cancer stem cells 159
Plasma Interleukin-8 is a biomarker for TAK1 activation and predicts resistance to nanoliposomal irinotecan in patients with gemcitabine-refractory pancreatic cancer 157
Data demonstrating the role of peroxiredoxin 2 as important anti-oxidant system in lung homeostasis. 154
Clinicogenomic Analysis of FGFR2-Rearranged Cholangiocarcinoma Identifies Correlates of Response and Mechanisms of Resistance to Pemigatinib 154
The development of PARP as a successful target for cancer therapy 153
Adjuvant chemotherapy is associated with improved postoperative survival in specific subtypes of invasive intraductal papillary mucinous neoplasms (IPMN) of the pancreas: it is time for randomized controlled data 153
AGENTI BIOLOGICI e CHEMIOTERAPICI: INTEGRAZIONE 151
TAK1-regulated expression of BIRC3 predicts resistance to preoperative chemoradiotherapy in oesophageal adenocarcinoma patients 151
TGF-beta-activated Kinase 1 (TAK1) is a therapeutic target modulating pancreatic cancer chemoresistance 150
PEROXIREDOXIN-2: A NOVEL REGULATOR OF IRON HOMEOSTASIS IN INEFFECTIVE ERYTHROPOIESIS 149
Role of next-generation genomic sequencing in targeted agents repositioning for pancreaticoduodenal cancer patients 148
Modulation of pancreatic cancer chemoresistance by inhibition of TAK1. 147
Screening/surveillance programs for pancreatic cancer in familial high-risk individuals: A systematic review and proportion meta-analysis of screening results 147
Modulating TAK1 expression inhibits YAP and TAZ oncogenic functions in pancreatic cancer 147
Prognostic Impact of Preoperative Nutritional Risk in Patients Who Undergo Surgery for Pancreatic Adenocarcinoma 147
Novel Biomarkers for Prediction of Response to Preoperative Systemic Therapies in Gastric Cancer 144
EMT and Treatment Resistance in Pancreatic Cancer 143
Angiogenesis: A target for cancer therapy. 142
Pancreatic Cancer: between bench and bedside. 140
A novel modified CpG inhibits EGF receptor signalling and synergistically enhances antitumor activity of cetuximab and irinotecan in colon cancer xenografts. 139
Pro-inflammatory factors secreted by pancreatic cancers with evasive resistance to anti-VEGF treatment contribute to malignant progression by inducing EMT 137
Antitumor activity of ZD6126, a novel vascular-targeting agent, is enhanced when combined with ZD1839, an epidermal growth factor receptor tyrosine kinase inhibitor, and potentiates the effects of radiation in a human non-small cell lung cancer xenograft model. 136
Mechanisms of resistance to chemotherapeutic and anti-angiogenic drugs as novel targets for pancreatic cancer therapy 136
Second-line chemotherapy for advanced pancreatic cancer: Which is the best option? 136
Germinal BRCA1-2 pathogenic variants (gBRCA1-2pv) and pancreatic cancer: epidemiology of an Italian patient cohort 134
From Genetic Alterations to Tumor Microenvironment: The Ariadne's String in Pancreatic Cancer 133
Multicenter Retrospective Analysis of Second-Line Therapy after Gemcitabine Plus Nab-Paclitaxel in Advanced Pancreatic Cancer Patients 133
KRAS wild-type pancreatic ductal adenocarcinoma: molecular pathology and therapeutic opportunities 132
R1507, the human monoclonal antibody targeting the Insulin-like Growth Factor Receptor (IGF-1R), in combination with cetuximab can reverse acquired resistance to cetuximab in pancreatic and colon cancer models 131
CT texture analysis of ductal adenocarcinoma downstaged after chemotherapy 131
Histogram analysis of magnetic resonance images: evaluation of intra-tumoral heterogeneity and correlation with pathological findings in solid pancreatic tumors. 131
MEKK3 Sustains EMT and Stemness in Pancreatic Cancer by Regulating YAP and TAZ Transcriptional Activity 131
Exceptional Clinical Response to Alectinib in Pancreatic Acinar Cell Carcinoma With a Novel ALK-KANK4 Gene Fusion 130
HER2 loss in HER2-positive gastric or gastroesophageal cancer after trastuzumab therapy: Implication for further clinical research 128
Targeting KRAS: The Elephant in the Room of Epithelial Cancers 127
ESGAR 2018 Book of Abstracts 126
Autotaxin Secretion Is a Stromal Mechanism of Adaptive Resistance to TGFβ Inhibition in Pancreatic Ductal Adenocarcinoma 124
Toll-Like Receptor 9 Agonists for Cancer Therapy 122
Peroxiredoxin-2 plays a pivotal role as multimodal cytoprotector in the early phase of pulmonary hypertension 119
Pemigatinib, a potent inhibitor of FGFRs for the treatment of cholangiocarcinoma 119
Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy. 118
Therapeutic integration of signal transduction targeting agents and conventional anti-cancer treatments. 118
Predictive biomarkers for the treatment of resectable esophageal and esophago-gastric junction adenocarcinoma: from hypothesis generation to clinical validation 118
Toll-like receptor 9 agonist IMO cooperates with cetuximab in K-ras mutant colorectal and pancreatic cancers 117
Gefitinib ('Iressa, ZD1839') and a second generation antisense targeting murine double minute 2 (Mdm2) synergistically inhibit tumor growth and angiogenesis in hormone-refractory prostate cancer 117
Rare secondary tumors of the pancreas 116
Emerging pathways and future targets for the molecular therapy of pancreatic cancer. 116
Combination of a selective cyclooxygenase-2 inhibitor with EGFR tyrosine kinase inhibitor ZD1839 (‘Iressa’) and Protein Kinase A antisense causes a cooperative antitumor and antiangiogenic effect 115
Clinical Response to Futibatinib in Patients with High-Level FGFR2-Amplified Advanced Gastric Cancer: Two Case Reports 114
Predictive Biomarkers for a Personalized Approach in Resectable Pancreatic Cancer 114
HOX Genes Family and Cancer: A Novel Role for Homeobox B9 in the Resistance to Anti-Angiogenic Therapies 114
Pathologic angiogenesis in the bone marrow of humanized sickle cell mice is reversible by blood transfusion 112
Novel Toll-like receptor 9 (TLR9) agonist IMO inhibits tumor growth and cooperates with cetuximab in K-Ras mutant colon and pancreatic cancer 111
TGF-beta activated kinase 1 (TAK1) is a drugable target for pancreatic cancer (PC) 109
TAK-ing aim at chemoresistance: The emerging role of MAP3K7 as a target for cancer therapy 109
Toll-like receptor 9 agonist IMO cooperates with cetuximab in K-ras mutant colorectal and pancreatic cancers. 108
Targeting the epidermal growth factor receptor in solid tumors: focus on safety. 108
The curious case of Gαs gain-of-function in neoplasia 108
Selecting patients for gastrectomy in metastatic esophago-gastric cancer: clinics and pathology are not enough 108
Human cancer cells with acquired resistance to anti-EGFR therapy are inhibited by VEGF- and EGFR-receptors tyrosine kinase inhibitor ZD6474 107
Vascular endothelial growth factor receptor-1 contributes to resistance to anti-epidermal growth factor receptor drugs in human cancer cells 107
Molecular analysis of a male breast cancer patient with prolonged stable disease under mTOR/PI3K inhibitors BEZ235/everolimus 105
Zoledronic acid cooperates with a cyclooxygenase-2 inhibitor and gefitinib in inhibiting breast and prostate cancer. 104
LY2109761, a novel transforming growth factor beta receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis. 104
TGF-beta-activated kinase 1 (TAK1) is an in vivo druggable target for reverting pancreatic cancer chemoresistance 104
Zoledronic acid (ZOMETA) in combination with a COX-2 inhibitor and gefitinb ('Iressa, ZD1839') cooperatively inhibits growth and angiogenic factor expression and secretion in breast and prostate carcinoma cells 104
Quality-adjusted survival with combination nal-IRI+5-FU/LV vs 5-FU/LV alone in metastatic pancreatic cancer patients previously treated with gemcitabine-based therapy: a Q-TWiST analysis 104
Permissive State of EMT: The Role of Immune Cell Compartment 104
The Multifaceted Role of TGF-β in Gastrointestinal Tumors 103
Perioperative NALIRIFOX in patients with resectable pancreatic ductal adenocarcinoma: The open-label, multicenter, phase II nITRO trial 102
Key cancer cell signal transduction pathways as therapeutic targets. 102
Zoledronic acid (ZOMETA) in combination with a COX-2 inhibitor and gefitinib ('Iressa') cooperatively inhibits growth and angiogenic factor expression in breast and prostate carcinoma cells. 102
Outcomes of Advanced Gastric Cancer Patients Treated with at Least Three Lines of Systemic Chemotherapy 102
Serum CA 19-9 level as a surrogate marker for prognosis in locally advanced pancreatic cancer (LAPC). 101
Totale 14.121
Salva come PNG Salva come JPEG
Categoria #
all - tutte 66.065
article - articoli 56.566
book - libri 0
conference - conferenze 7.936
curatela - curatele 0
other - altro 419
patent - brevetti 0
selected - selezionate 0
volume - volumi 1.144
Totale 132.130
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021489 0 0 0 0 0 134 8 69 34 58 107 79
2021/20221.221 87 433 13 167 15 15 9 62 38 22 68 292
2022/20232.311 180 234 221 357 209 553 28 138 293 23 49 26
2023/20241.331 43 101 94 123 164 183 116 166 15 71 198 57
2024/20253.233 167 191 110 510 138 99 177 160 491 200 311 679
2025/20266.094 686 430 685 1.424 2.274 595 0 0 0 0 0 0
Totale 18.303